21 reports

There is evidently a need for more epidemiological research, especially in European markets, to collect more robust, recent prevalence data and highlight novel environmental and genetic risk factors for this condition.

  • Renal Disease
  • Europe
  • Japan
  • Amgen Inc.
  • Roche Group

IDENTIFICATION OF NOVEL GENETIC MARKERS ASSOCIATED WITH CLINICAL PHENOTYPES OF SYSTEMIC SCLEROSIS THROUGH A GENOME-WIDE ASSOCIATION STRATEGY.

  • Renal Disease
  • France
  • Italy
  • World
  • Forecast
  • UPDATES
  • Renal Disease
  • Angion Biomedica Corp.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Clinical Trials by G7 Countries: Proportion of Polycystic Kidney Disease to Genetic Disorders Clinical Trials
  • Clinical Trials by E7 Countries: Proportion of Polycystic Kidney Disease to Genetic Disorders Clinical Trials
  • Pharmaceutical
  • Renal Disease
  • World
  • Product Initiative
  • Otsuka Pharmaceutical Co., Ltd.
  • Renal Disease
  • United States
  • World
  • Product Initiative
  • CTI BioPharma Corp.
  • Renal Diseases, Global, Pipeline Programs Targeting Connective Tissue Growth Factor, 2017
  • Renal Diseases, Global, AKI Types, 2017

Other causes include reduced blood supply to the kidneys, obstruction of the urinary tract and genetic alterations.

  • Chronic Disease
  • Renal Disease
  • World
  • Deals & Alliance
  • Galectin Therapeutics Inc.

The company' s target therapeutic areas include rheumatoid arthritis, HIV/ AIDS, respiratory infections, cancer, diabetes, men' s and women' s health, and genetic conditions.

  • Diabetes
  • Renal Disease
  • World
  • Forecast
  • Sysmex Corporation
  • POLYCYSTIC KIDNEY DISEASE - DORMANT PROJECTS, H2 2017
  • DBM-43H11 - DRUG PROFILE

Genetic knockdown of HDAC## in CLL cells reduced Discovery/ Preclinical Trial Details expression of PD-L## and other immune checkpoint markers, while increasing markers related to antigen presentation, including MHC II.

  • Hormone
  • Renal Disease
  • United States
  • Company
  • Product Initiative

The invention relates to genetically modified mesenchymal stem cells (MSCs) and their use as a medicament in the treatment of a tumors.

  • Chronic Disease
  • Genitourinary System Disease
  • Renal Disease
  • United States
  • Product Initiative

In a separate poster presentation, ChemoCentryx presented details of the creation of a colony of genetically unique mice that are designed to assess the effects of inhibiting the C##aR with CCX## on diseases characterized by unregulated complement activation, such as atypical hemolytic urem

  • Renal Disease
  • Therapy
  • United States
  • Product Initiative
  • ChemoCentryx, Inc.

Genetic Epidemiology and Other Genetic Studies of Common Kidney Diseases FR-PO## CKD and AKI Clinical Trials Date & Time: Thursday, ##/ ##/ 2016, ##:## PM - ##:## PM CT Location: S## The abstracts can be accessed through the ASN Kidney Week 2016 website.

  • Renal Disease
  • Therapy
  • United States
  • Product Initiative
  • ChemoCentryx, Inc.
  • MAR 21, 2017: WORLD LEADING PREDICTIVE DIAGNOSTIC TEST FOR DIABETIC KIDNEY DISEASE CRISIS TO ROLL-OUT IN ASIA WITH CHINA AND SINGAPORE PATENTS AND COMMERCIALISATION PARTNERS

It is a powerful alternative to genetic testing.

  • Diagnostics
  • Renal Disease
  • Australia
  • United States
  • GlobalData's company
  • Polycystic Kidney Disease - Companies Involved in Therapeutics Development
  • Polycystic Kidney Disease - Dormant Projects

" This study represents our ongoing commitment to patients with this rare genetic condition to provide them and their physicians with a novel treatment option. "

  • Renal Disease
  • United States
  • World
  • Company
  • Product Initiative

It provides research origins on cancer and inflammation therapies by utilizing the genetic information and analysis technology.

  • Genitourinary System Disease
  • Pharmaceutical
  • Prosthesis
  • Renal Disease
  • Angion Biomedica Corp.

The disease in children is generally from genetic origin while adults mostly develop dRTA as a result of autoimmune disease.

  • Clinical Trial
  • Drug Discovery And Development
  • Renal Disease
  • Therapy
  • World
  • CHRONIC KIDNEY DISEASE (CHRONIC RENAL FAILURE) - PIPELINE BY IONIS PHARMACEUTICALS, INC., H1 2016

Determine genetic, mammalian cell, cardiac, and liver toxicity of ##FP ##.

  • Diabetes
  • R&D
  • Renal Disease
  • Research And Development
  • RVX-208 group

It provides research origins on cancer and inflammation therapies by utilizing the genetic information and analysis technology.

  • Diabetes
  • Genitourinary System Disease
  • Renal Disease
  • United States
  • Product Initiative
  • 5. All the trials included are unique trials.

Genetic Engineering and Biotechnology Heber Biotec S A ## Oct 2009 ## ## ## Hepatitis C Virus Envelope Protein E##; Hepatitis C Virus Envelope Protein E## Safety, PK/ PD, and Efficacy of NOX-H## in Dialysis Patients with ESA-hyporesponsive Anemia: A Randomized, Double Blind, Placebo Control

  • Clinical Trial
  • Hormones
  • Pharmaceutical
  • Renal Disease
  • World
  • IONIS PHARMACEUTICALS, INC.

genetic disorders marked by severely high triglyceride levels; IONIS-TTRRx, a first-in-class drug for the treatment of all forms of TTR amyloidosis and Nusinersen being developed for the spinal muscular atrophy (SMA).

  • Hospital
  • Renal Disease
  • United States
  • Product Initiative
  • Bayer AG

Genetic Resistance". ##-May-2014 Cell Therapeutics, Inc. has announced that it will change its corporate name to CTI BioPharma Corp. and the change of the company' s name will entail with effective from May ##, 2014.

  • Pathology
  • Pharmaceutical
  • Renal Disease
  • United States
  • CTI BioPharma Corp.

Genetic Engineering and Biotechnology Heber Biotec S.

  • Clinical Trial
  • Drug Discovery And Development
  • Pharmaceutical
  • Renal Disease
  • World